Efficacy, Safety, Tolerability and Quality of Life of Ongoing Individually Optimized Lipid-lowering Therapy With or Without Inclisiran (KJX839) - a Randomized, Placebo-controlled, Double-blind Multicenter Phase IV Study in Participants With Hypercholesterolemia
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Inclisiran (Primary) ; Rosuvastatin (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms V-DIFFERENCE
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 06 Apr 2025 Status changed from active, no longer recruiting to completed.
- 30 May 2024 Status changed from recruiting to active, no longer recruiting.
- 08 May 2024 Planned primary completion date changed from 26 Feb 2025 to 27 May 2024.